Click HERE to download the PDF

AFTER THE ACQUISITION OF YPOSKESI THAT ALLOWED SK PHARMTECO TO ENTER THE CELL AND GENE THERAPY MARKET, ARE THERE ANY OTHER EXPANSION PLANS YOU WOULD LIKE TO HIGHLIGHT?
This is an exciting area for us. Our goal is to become the largest global, end-to-end cell and gene therapy (CGT) CDMO. In April 2021, we acquired Yposkesi and recently, we entered into an exclusive final negotiation with the Center for Breakthrough Medicines (CBM). We are going to add capacity at both sites. At Yposkesi, we are adding 1 x 1000 L capacity in Q1’ 2022 and have also started construction of a new commercial facility that will include 4 x 1000 L bioreactors. This will more than double our capacity to manufacture clinical and commercial batches at Yposkesi.

...